GO
Loading...

Allergan Inc

More

  • Pershing Square surges 25% in first half Thursday, 3 Jul 2014 | 1:15 PM ET
    Bill Ackman

    William Ackman's main fund climbed 25% during the first half of 2014, ranking him as one of the year's top hedge fund industry performers.

  • Strong gains in its top holdings, including Canadian Pacific, Air Products& Chemicals and Burger King Worldwide helped fuel the rise. Ackman has spent much of June trying to convince pharmaceutical company Allergan, in which he is the biggest investor, to sell itself to rival Valeant Pharmaceuticals, with which he is working to negotiate a deal.

  • BOSTON, July 1- Activist investor William Ackman has hired Credit Suisse in his fight to have Valeant Pharmaceuticals acquire Botox maker Allergan Inc., a person familiar with the matter said on Tuesday.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • TIMELINE-Ackman and Valeant maneuver for Allergan Tuesday, 1 Jul 2014 | 2:02 PM ET

    July 1- Valeant Pharmaceuticals International Inc has teamed up with Pershing Square Capital Management, led by activist investor William Ackman, to make a run at Botox maker Allergan Inc. Here are the details of some of the most interesting steps along the way.

  • NEW YORK and LOS ANGELES, July 1- Allergan Inc may take on debt to buy back its own shares as part of a multi-faceted plan to thwart a $53 billion takeover bid by Valeant Pharmaceuticals International Inc and activist investor William Ackman.

  • NEW YORK, June 30- Most investments came up winners in the first half of 2014, which came to a close on Monday with solid gains for U.S. stocks, U.S. Treasuries, muni bonds, oil and gold. Forest Labs +64.9 Keurig Green +65.0.

  • June 30- Allergan Inc said on Monday that the U.S. Food and Drug Administration would not approve its acute migraine aerosol treatment until certain concerns are addressed, but the agency approved a new use for its implantable eye drug, Ozurdex.

  • Midday movers: Allergan, MBIA, Treehouse Foods & More Monday, 30 Jun 2014 | 12:13 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • June 30- Allergan Inc said on Monday the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine aerosol but had separately approved a treatment for diabetic macular edema.

  • June 30- Allergan Inc on Monday said the U.S. Food and Drug Administration had raised issues about its application for a new acute migraine treatment and that it was working with the agency to address them.

  • Let's make a deal! Global M&A at 7-year high Monday, 30 Jun 2014 | 6:21 AM ET
    Viagra made by Pfizer and Nexiam made by AstraZeneca.

    Investor support for large acquisitions and a desire to trump rivals in consolidating markets have led CEOs to strike big transactions in 2014.

  • NEW YORK, June 30- Investor support for large acquisitions and a desire to trump rivals in consolidating markets have led chief executives to strike big transactions so far in 2014, raising year-to-date global deal volumes to their highest level in seven years.

  • June 27- Pershing Square Capital Management, led by activist investor William Ackman, and Allergan Inc have agreed that calling a special meeting in an effort to elect new board members will not trigger Allergan's so-called "poison pill" measure, settling a lawsuit, the companies said on Friday.

  • Paulson & Co said to amass large stake in Allergan Wednesday, 25 Jun 2014 | 4:53 PM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    Hedge fund Paulson & Co has amassed a large stake in Allergan and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals.

  • New York, June 25- Hedge fund Paulson& Co has amassed a large stake in Allergan Inc of more than 6 million shares and is supportive of a deal between the Botox maker and Valeant Pharmaceuticals Inc, people familiar with the matter on Wednesday.

  • Early movers: MU, AAPL, DF, MCRS & more Tuesday, 24 Jun 2014 | 7:50 AM ET
    Traders work the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Insider trading: How rogue is it? Monday, 23 Jun 2014 | 1:41 PM ET

    The authors of the recent study on insider trading that had Wall Street abuzz go a step further on exactly how rogue it is.

  • *$46 bln offer from AbbVie rejected as undervaluing group. LONDON, June 23- Shire flagged the promise of existing and new drugs on Monday as evidence that AbbVie's $46 billion offer undervalued the company, the latest British firm to be targeted by a U.S. group seeking lower taxes.

  • Allergan rejects Valeant's takeover bid...again Monday, 23 Jun 2014 | 10:53 AM ET
    A doctor draws Allergan Inc. Botox into a syringe before administering it to a patient at the offices of Marcus Facial Plastic Surgery in Redondo Beach, California

    Allergan advised investors not to sell their shares to Valeant, which launched a hostile takeover offer for the Botox maker last week.